Monthly Archives: July 2017


Canadian clinics begin offering stem-cell treatments experts call unproven, possibly unsafe – National Post

The arthritis in Maureen Munsies ankles was so intense until barely a year ago, she literally had to crawl on hands and knees to get upstairs.

The pain, she recalls now, took my breath away, and played havoc with the avid hikers favourite pastime.

In desperation, Munsie turned to a Toronto-area clinic that provides a treatment many experts consider still experimental, unproven and of questionable safety.

The 63-year-old says the stem cells she received at Regenervate Medical Injection Therapy 18 months ago were transformational, all but eliminating the debilitating soreness and even allowing her to hike Argentinas Patagonia mountains two months ago.

For me its been a life saver, Munsie says. Ive been able to do it all again I dont have any of that pain, at all.

Canadians drawn to the healing promise of stem cells have for years travelled outside the country to such places as Mexico, China or Arizona, taking part in a dubious form of medical tourism.

But Regenervate is one of a handful of clinics in Canada that have begun offering injections of stem cells, satisfying growing demand but raising questions about whether a medical idea with huge potential is ready for routine patient care.

Especially when those patients can pay thousands of dollars for the service.

Clinics in Ontario and Alberta are treating arthritis, joint injuries, disc problems and even skin conditions with stem cells typically taken from patients fat tissue or bone marrow.

The underlying idea is compelling: stem cells can differentiate or transform into many other types of cell, a unique quality that evidence suggests allows them to grow or regenerate tissue damaged by disease or injury.

Researchers including hundreds in Canada alone are examining stem-cell treatments for everything from ailing hearts to severed spinal cords.

With few exceptions, however, the concept is still being studied in the lab or in human trials; virtually none of the treatments have been definitively proven effective by science or approved by regulators like Health Canada.

The fact that Canadian clinics are now offering stem-cell treatments commercially is concerning on a number of levels, not least because of safety issues, says Ubaka Ogbogu, a health law professor at the University of Alberta.

Three U.S. women were blinded after receiving stem-cell injections in their eyes, while other American patients have developed bony masses or tumours at injection sites, Ogbogu said.

Stem cells have to be controlled to act exactly the way you want them to act, and thats why the research takes time, he said. It is simply wrong for these clinics to take a proof of concept and run with it.

Ogbogu says Health Canada must crack down on the burgeoning industry but says the regulator has so far been conspicuous by its inaction.

Other experts say the procedures provided here typically for joint pain are likely relatively safe, but still warn that care must be taken that the stem cells do not develop into the wrong type of tissue, or at the wrong place.

Alberta Health Services convened a workshop on the issue late last year, concluding there is an urgent need to develop a certification system for cell preparation and delivery to avoid spontaneous transformation of (stem cells) into unwanted tissue.

But one of the pioneers of the service in Canada says theres no empirical evidence that such growths can develop, and suggests the treatments only real risk as with an invasive procedure is infection.

Meanwhile, patients at Regenervate have enjoyed impressive outcomes after paying fees from $750 to $3,900, says Dr. Douglas Stoddard, the clinics medical director.

About 80 per cent report less pain, stiffness and weakness within a few months of getting their stem-cell injection, he said.

I believe medical progress is not just limited to the laboratory and randomized double-blind trials, Stoddard said. A lot of progress starts in the clinic, dealing with patients You see something works, you see something has merit, and then its usually the scientists that seem to catch up later.

The Orthopedic Sport Institute in Collingwood, Ont., the Central Alberta Pain and Rehabilitation Institute and Cleveland Clinic in Toronto all advertise similar stem-cell treatments for orthopedic problems.

Edmontons Regen Clinic says it plans to start doing so this fall.

Ottawas Innovo says it also treats a range of back conditions with injections between the vertebrae, and uses stem cells to alleviate nerve damage.

Orthopedic Sport says its doctor focuses on FDA and Health Canada approved stem-cell injection therapy for patient care.

In fact, no treatment of the sort the clinics here provide has ever been authorized.

Health Canada says the vast majority of stem-cell therapies would constitute a drug and therefore need to be authorized after a clinical trial or new drug submission.

A number of stem-cell trials are underway, but only one treatment Prochymal has been approved, said department spokesman Eric Morrissette. Designed to combat graft-versus-host disease where bone marrow transplants for treating cancer essentially attack the patients body its unlike any of the services the stem-cell providers here offer.

But as the U.S. Food and Drug Administration aggressively pursues the hundreds of clinics in America, Health Canada says only that its committed to addressing complaints it receives.

It will take action based on the risk posed to the general public, said Morrissette, who encouraged people to pass on to the department information about possible non-compliant products.

Stoddard said the injections his clinics provide are made up of minimally manipulated tissue from patients own bodies and any attempt to crack down would be regulation for the sake of regulation.

But academic experts remain skeptical about the effectiveness of the treatments.

Scientific evidence suggests the injections may help alleviate joint pain temporarily, but probably just because of anti-inflammatory secretions from the cells not regeneration, said Dr. David Hart, an orthopedic surgery professor at the University of Calgary who headed the Alberta workshop.

Theres a need for understanding whats going on here and theres a need for regulation, he said.

Most of the clinics say they use a centrifuge to concentrate the stem cells after removing them from patients fat tissue or bone marrow. But its unclear if the clinics even know how many cells they are eventually injecting into patients, says Jeff Biernaskie, a stem-cell scientist at the University of Calgary.

Munsie, on the other hand, has no doubts about the value of her own treatment, even with a $3,000 price tag.

The procedure from extraction of fat tissue in her behind to the injection of cells into her ankles took barely over an hour.

Within three months, the retired massage therapist from north of Toronto says she could walk her dogs again. Last week, she was hiking near Banff.

Im a real believer in it, and the possibility of stem cells, says Munsie. I just think Wow, if we can heal with our own body, its pretty amazing.

tblackwell@nationalpost.com

More:
Canadian clinics begin offering stem-cell treatments experts call unproven, possibly unsafe - National Post

Stem cell-based therapies to treat spinal cord injury: a review – Dove Medical Press

Zhongju Shi,1,2 Hongyun Huang,3 Shiqing Feng1,2

1Department of Orthopaedics, Tianjin Medical University General Hospital, 2Institute of Neurology, Key Laboratory of Post-Neuroinjury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education, Tianjin City, Tianjin, 3Institute of Neurorestoratology, General Hospital of Armed Police Forces, Beijing, Peoples Republic of China

Abstract: Spinal cord injury (SCI) is a devastating condition and major burden on society and individuals. Currently, neurorestorative strategies, including stem cell therapy products or mature/functionally differentiated cell-derived cell therapy products, can restore patients with chronic complete SCI to some degree of neurological functions. The stem cells for neurorestoration include neural stem cells, mesenchymal stem cells, embryonic stem cells, induced pluripotent stem cells, etc. A better understanding of the merits, demerits and precise function of different stem cells in the treatment of SCI may aid in the development of neurorestorative strategies. However, the efficacy, safety and ethical concerns of stem cell-based therapy continue to be challenged. Nonetheless, stem cell-based therapies hold promise of widespread applications, particularly in areas of SCI, and have the potential to be novel therapeutics, which contributes to the repair of SCI. This review mainly focused on recent advances regarding the stem cell-based therapies in the treatment of SCI and discussed future perspectives in this field.

Keywords: spinal cord injury, neural stem cells, bone marrow-derived mesenchymal stem cells, adipose-derived stem cells, embryonic stem cells, induced pluripotent stem cells

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Read the original post:
Stem cell-based therapies to treat spinal cord injury: a review - Dove Medical Press

Stem Cell Assay Market Driven by Rising Diversity of Applications – TMR Research Blog (press release) (blog)

San Francisco, California, July 03, 2017: TMR Research announces a new report on the global stem cell assay market. The report examines the historical growth trajectory exhibited by the global stem cell assay market and its latest figures, and further provides reliable forecasts for the stem cell assay market based on complete analysis of the markets database. The report also takes a close look at the regional and competitive dynamics of the global stem cell assay market in order to shed light on the dynamics of the global market more clearly. The report is titled Stem Cell Assay Market Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 2025.

Testing antineoplastic drugs in order to check their potency in cancer treatment has emerged as a major application for the global stem cell assay market. The testing covers impurity, toxicity, and other aspects of the tumors and provides a qualitative and quantitative analysis of various aspects of the tumor. The comprehensive figures provided by stem cell assays has driven the demand from the global stem cell assay market.

The growing diversity of applications of stem cell assays is likely to be a major driver for the global stem cell assay market. Pluripotent stem cells have been used in the treatment of several diseases so far and are likely to remain a key part of the healthcare sector in the coming years due to their intrinsic potential to transform into a wide variety of cells in the human body. This makes them a highly promising research avenue in the treatment of diverse conditions such as Alzheimers, Parkinsons, diabetes, rheumatoid arthritis, and retinal diseases, apart from cancer. The growing prevalence of neurological and neurodegenerative conditions, particularly among the growing geriatric demographic in developed countries, is thus likely to be a major driver for the global stem cell assay market.

Steady research and development in the medical sector is likely to remain a key driver for the global stem cell assay market, as the diversity of application of stem cells is purely potential until applied to specific avenues. Growing government support to the medical sector is likely to help the global stem cell assay market in this regard, as significant investment is required to carry out advanced medical research.

Regionally, North America and Europe are likely to remain the leading contributors to the global stem cell assay market due to the presence of a stable healthcare sector in developed countries in the region. The ready incorporation of technological advancements such as stem cell assays in the day to day functioning of the healthcare sector is the key driver for the stem cell assay market in developed countries such as the U.S., Canada, the U.K., Germany, and France.

The report also profiles leading players in the global stem cell assay market in order to shed light on the competitive dynamics of the market. Stem cell assay market leaders examined in the report include Thermo Fisher Scientific Inc., GE Healthcare, STEMCELL Technologies Inc., Bio-Rad Laboratories Inc., Hemogenix Inc., Cell Biolabs Inc., and Promega Corporation.

Like Loading...

Continue reading here:
Stem Cell Assay Market Driven by Rising Diversity of Applications - TMR Research Blog (press release) (blog)

Regenerative medicine helps achy pets – WFLA

TAMPA, FL. Don and Judy Schmeling consider their chocolate lab, Alexandra, a member of the family.

We have three boys, says Judy. We like to say Alex is our girl.

When, at age nine, Alex started having knee pain, the Schmelings consulted their veterinarian, who suggested regenerative medicine, in the form of stem cell treatment.

Judy says, We decided to do it because she was still so young and had quite a few years ahead of her. We wanted her to have quality of life.

Dr. Farid Saleh of Ehrlich Animal Hospital removed a small amount of fat from Alexs belly, harvested the cells, and injected them into her knee during a same-day procedure performed at on site.

Youregiving the body a chance to regrow tissue instead of trying to heal or manage the diseased tissue thats there, explains Dr. Saleh.

After a few months, Alex was back to her old self. Shes now 12 years old.

Sometimes she acts like a puppy! Its been amazing, Judy says.

Alexs stem cells were harvested when she needed them, however Dr. Saleh says its not a bad idea to harvest them when pets are younger and under anesthesia for a procedure like a teeth cleaning.

If we could harvest something that we can use in the future to help our pets get better, it would be an amazing thing, says Dr. Saleh.

Stem cells can be stored, although doing so often requires a third-party company, and theres an annual fee. As for the harvesting and stem cell treatments, they average $2,500. The most common uses are for arthritis, and injuries to bones and joints. Less often, stem cell therapy is used to treat tumors. And, research indicates that stem cell therapy may be an option for treating chronic diseases.

STORIES OTHERS ARE CLICKING ON:

BACK TO TOP STORIES

Here is the original post:
Regenerative medicine helps achy pets - WFLA

TissueGene awarded $750000 Maryland Stem Cell Grant for Invossa clinical study – BSA bureau (press release)

The grant award will be used by TissueGene to fund a component of a clinical study at a Maryland location for its US Phase III clinical trial for Invossa.

Singapore -TissueGene, Inc., aUS-based regenerative medicine company, announced that the Maryland Stem Cell Research Fund (MSCRF) has awarded TissueGene a clinical grant for Invossa, the world's first cell and gene therapy for degenerative arthritis.

The clinical grant is to be used for conducting clinical trials inMarylandusing cell therapy. This money is part of Accelerating Cure, a new TEDCO initiative to support regenerative medicine and cell therapy technologies in Maryland.

The grant award will be used by TissueGene to fund a component of a clinical study at aMaryland location for its US Phase III clinical trial for Invossa. The ultimate outcome of this study is the verification that Invossa exerts its therapeutic effect not only by tissue regeneration but on other inflammatory aspects of the disease such as synovitis.

The title of the grant is "Assessment of the Efficacy of TG-C in Treating Synovitis Using Contrast Enhanced MRI in a Clinical Study of Knee Osteoarthritis." The Principal Investigator (PI) for the study will be Dr.Gurdyal Kalsi, Chief Medical Officer of TissueGene.

"We are excited to support this important clinical trial and the growth of TissueGene inMaryland," said Dr.Dan Gincel, TEDCO's VP University Partnerships, and MSCRF's Executive Director. "We look forward to see many more patients treated and cured from this and other devastating diseases."

Invossa is a first-in-class osteoarthritis drug designed to conveniently and effectively treat osteoarthritis of the knee through a single intra-articular injection. Clinical trials completed in Korea and on-going trials in the US have demonstrated pain relief, increased mobility, and improvements in joint structure offering substantial convenience for nearly 33 million Americans with osteoarthritis who would otherwise need surgery.

Visit link:
TissueGene awarded $750000 Maryland Stem Cell Grant for Invossa clinical study - BSA bureau (press release)

Stem Cell Therapy for Type 1 Diabetes – Medical News Bulletin

For over 20 years autologous hematopoietic stem cell treatment (AHSCT) has been a therapy for autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and lupus; however, the exact mechanism of action remains unclear. Recent clinical research has also been exploring the use of stem cell therapy for type 1 diabetes, another autoimmune disease which affects over 422 million individuals globally.

Type 1 diabetes, formerly known as juvenile or insulin-dependent diabetes, is a chronic condition where little or no insulin is produced by the pancreas. Immune cells attack pancreatic beta cells which produce insulin, leading to inflammation. Insulin is an essential hormone for energy production as it enables the breakdown of sugars to enter the cells and produce energy. The onset of type 1 diabetes occurs when significant inflammation damages beta cells and results in insufficient maintenance of glucose haemostasis (balance of insulin and glucagon to maintain blood glucose levels).

Therapies currently used in type 1 diabetes treatment include insulin administration, blood glucose monitoring and screening for common comorbidities and diabetes-related complications. However, these treatments fail to reduce the damage on a patients immune system. The use of autologous hematopoietic stem cells as a potential type 1 diabetes therapy is based upon the ability of the stem cells to reset the immune system. Autologous hematopoietic stems cells are retrieved from a patients own bone marrow or peripheral blood (blood which circulates the body and contains red blood cells, white blood cells and platelets) and after conditioning are injected intravenously.

A recent study by Ye and colleagues published in Stem Cell Research & Therapy (2017) investigated the effects AHSCT had on the immune response in recently diagnosed diabetes type 1 patients. The study included 18 patients (12-35 years old) with type 1 diabetes who had been diagnosed within less than 6 months. Of these 18 participants, 10 received a traditional insulin injection as treatment and eight received AHSCT. An additional 15 patients who matched in age, gender and BMI of these two groups were enrolled as a control group.

To test the effects of the treatment on immune response, patients peripheral blood cells were assessed. Samples were taken before they started treatment and then again 12 months after either the AHSCT or insulin-only therapies were administered.

Before treatment, peripheral blood cell distribution was almost equivalent in the two groups; however, after 12 months a significant difference was observed. The results of this clinical trial showed that patients receiving AHSCT exhibited significantly reduced development and function of Th1 and Th17 cells (types of T cells which cause inflammation in autoimmune diseases), compared to those only receiving the insulin treatment.

The inhibition of T-cell proliferation and function, along with decreased production of cytokines (pivotal chemical messengers which aid an immune response) observed in patients receiving AHSCT treatment suggests there is a strong link between the therapy and effects on the patients immune response. This may explain why AHSCT results in better therapeutic effects when compared with insulin-only traditional therapy.

The authors note that the small number of participants and length of the study are the two main limitations. Future clinical studies should include a larger number of patients and long-term follow up, especially since AHSCT can cause damage to the bone marrow and lead to potentially serious infections.

Progression of type 1 diabetes, as mentioned above, results in unavoidable immune damage from inflammation. This study suggests the combination of therapies including AHSCT treatment and high-dose immunosuppressive drugs may be a potential new therapeutic approach to type 1 diabetes. It is hypothesized that this combination has the ability reset the immune system and increase the recovery capacity of beta cells. Further clinical studies are essential though, to shed more light on the mechanism and use of stem cell therapy for type 1 diabetes.

Written By:Lacey Hizartzidis, PhD

See the original post here:
Stem Cell Therapy for Type 1 Diabetes - Medical News Bulletin

3D Bone-Like Tissues Grown From Stem Cells – Asian Scientist Magazine

AsianScientist (June 28, 2017) - Researchers at the University of Tokyo have developed a cell culture method that generates three-dimensional bone-like tissues from mouse pluripotent stem cells using only small molecules as inducers. The current result, published in Science Advances, is a step toward the generation of three-dimensional tissues in cell culture which mimic or are patterned after our organs.

Three-dimensional tissue-like structures, called organoids, are generated in cell culture using various cell types derived from pluripotent stem cells. These include embryonic stem cells and induced pluripotent stem cellscells reprogrammed to act like embryonic stem cells, which can differentiate into most cell types. Our understanding of tissue formation processes, regenerative medicine and drug development stand to benefit from the study and development of such organoids.

However, most studies to date involve cell-to-cell transfer of genetic material, recombinant proteins, the sera of calf fetuses and other substances of unknown composition, which raise safety and cost concerns.

In 2014, a group led by Associate Professor Shinsuke Ohba at the University of Tokyos Graduate School of Medicine developed a protocol that used only four small molecules to induce the formation of bone-forming cells (osteoblasts) from pluripotent stem cells. Building on this protocol in the present study, Ohba and his colleague, Professor Ung-il Chung (Yuichi Tei), succeeded in generating three-dimensional bone-like tissues from mouse pluripotent stem cells embedded within sponges composed of atelocollagencollagen molecules that do not trigger an immune response. These mouse pluripotent stem cells generated osteoblasts and osteocytes (mature bone cells).

In addition, when these stem cell-derived osteoblasts and osteocytes were cultured with progenitors of osteoclasts (bone-resorbing cells) in the sponge, mature osteoclasts were formed. These results suggested that the osteoblasts and osteocytes derived from mouse embryonic stem cells are functional, as they are in living bodies, with the ability to support osteoclast formation.

This research potentially leads to the generation of bone-like tissues in cell culture, in which three cell populations responsible for the formation and maintenance of our bones, namely osteoblasts, osteocytes, and osteoclasts, function in a three-dimensional manner, said Ohba.

We hope the strategy will contribute to our understanding of the origin and development of bone diseases, and help elucidate the mechanisms underlying the formation and maintenance of bones, as well as promote bone regenerative medicine and the development of drugs for treating bone diseases.

The article can be found at: Zujur et al. (2017) Three-dimensional System Enabling the Maintenance and Directed Differentiation of Pluripotent Stem Cells under Defined Condition.

Source: University of Tokyo. Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.

View original post here:
3D Bone-Like Tissues Grown From Stem Cells - Asian Scientist Magazine

Lack of stem cell donations plagues patients – Times of India

Visakhapatnam: Lack of awareness on the importance of becoming a blood stem cell donor is hindering the treatment of people suffering from blood cancer and other fatal blood disorders like thalassemia and aplastic anaemia.

Since the only cure is a blood stem cell transplant, the need of the hour is to sensitise people of the city on the necessity of becoming a potential blood stem cell donor to save lives, experts say.

According to oncologists based in Vizag, the cases of blood cancer are increasing and the treatment options are very few. Moreover, patients with blood cancer are sent to Hyderabad and other centres for treatment as neither there are donors nor equipment for stem cell transplant in the port city.

For a successful transplant, patients suffering from fatal blood disorders need blood stem cells from a healthy and genetically matched donor. Unfortunately, the probability of finding a genetically matched donor is one in 10,000 to one in over a million.

Only about 25 per cent of the patients find a donor from within their family. Rest need to wait for a life-saving donor.

"The chances of finding a match for patients suffering from these fatal blood disorders could only widen if there are more number of donors registered," says Ravindranath Chava, co-ordinator of a Chennai-based blood stem cell donors registry- DATRI.

More here:
Lack of stem cell donations plagues patients - Times of India

Doctors to offer stem cell treatments – The News (subscription)

Dr. Ren Halverson can empathize with his patients. Like many of those who walk through his doors at Advanced Chiropractic in Brunswick, he has also experienced injuries and the pain they cause.

I had a torn labrum in my right shoulder, a torn rotator cuff in my left shoulder and and torn meniscus in my right knee. I already had two surgeries on my knees, he said. It was a daily challenge treating patients.

In order to help his patients and himself find relief, the chiropractor is always on the lookout for the latest in scientific health developments that might help. He spends countless hours studying the latest in medical innovations. Not too long ago, Halversons research paid off when he came across amniotic stem cells.

Of course, Halverson was already familiar with stem cells and the long term research concerning some for joint treatment. But the new data, methods and results were something he simply couldnt ignore.

World-wide the results with stem cells are off the charts. There are different types of stem cells ... blood marrow, which is best used for blood diseases. Amniotic, which is the membrane surrounding the placenta and is the safeguard between the mothers blood flow and the babys. That is what we are talking about here, he said. It has proven to be best for joint and tendon repair.

Amniotic arent, however, the same as the controversial fetal stem cells that gained so much attention over the past decade. Halverson says these types of stem cells raise no moral or ethical questions. They are also more effective than other types of stem cells in healing musklo-skeletal injuries.

These are offered by willing, cesarean donors. The FDA has approved the process and it is very strictly regulated. The hosts, the mothers who donate, are screened for all blood born pathogens before they are able to donate.

The regenerative field of medicine is something that has proven itself invaluable over the past few decades. It has convinced Halverson to open that door to his patients. After all, he has experienced the positive effects of the treatment first hand.

I wanted to try the stem cell treatment first. I did it about three months ago and the results are just incredible, he said, moving his arms to illustrate his range of motion.

It takes about eight months for the full effects to set in but Im swimming again. I couldnt do that before. In many cases worldwide, patients have been able to fully heal arthritic joints and tendons or cartilage tears without having to have surgery.

He feels the statistics truly speak for themselves. The company Halverson uses has conducted more than 100,000 similar treatments.

Stem cells contain Hyaluronic Acid which provides a scaffold for mesenchymal growth cells to begin the rebuilding process. They also contain natural anti inflammatory agents known as Cytokines.

Halverson says there is not one documented case of a side effect reported.

There has never been a negative reaction. Patient satisfaction is/over 98 percent ... thats just in the U.S. They are doing this heavily in Europe and Israel, he said. The results are unbelievable. Pre- and post -X-rays show remarkable results.

He will however bring on new faces who will run the expanded medical clinic.

Our medical director is Dr. Theresa Cezar, who is a great internist but has extensive experience in physical medicine. We also have Cynthia White who is our nurse practitioner. They are both excellent, he said. We have a really exceptional staff here.

In addition to the stem cell treatments, Halverson is offering an expanded line of medical services, designed to treat musklo-skeletal patients with a cutting edge integrated approach. Those include trigger point injections, state of the art spinal bracing, biomechanics as well as the regeneration therapy, which includes stem cell and Hormone Replacement Therapy.

Halverson is excited about the opportunity to bring these innovative techniques to the Golden Isles. He sees these treatments as a significant building blocks in the future of healthcare, a departure from relying on medication, dangerous opioids and other invasive options.

Ive experienced it and I know it works. Even Medicare says integration with medicine, chiropractic and therapies together are the wave of the future. We are combining what weve already been doing ... the chiropractic and rehabilitation to really take this to the next level, Halverson said.

Read more here:
Doctors to offer stem cell treatments - The News (subscription)

Scientists Turn Back the Clock on Adult Stem Cells Aging …

Reversing the aging process could lead to medical treatments for many chronic conditions

Researchers have shown they can reverse the aging process for human adult stem cells, which are responsible for helping old or damaged tissues regenerate. The findings could lead to medical treatments that may repair a host of ailments that occur because of tissue damage as people age. A research group led by the Buck Institute for Research on Aging and the Georgia Institute of Technology conducted the study in cell culture, which appears in the September 1, 2011 edition of the journal Cell Cycle.

The regenerative power of tissues and organs declines as we age. The modern day stem cell hypothesis of aging suggests that living organisms are as old as are its tissue specific or adult stem cells. Therefore, an understanding of the molecules and processes that enable human adult stem cells to initiate self-renewal and to divide, proliferate and then differentiate in order to rejuvenate damaged tissue might be the key to regenerative medicine and an eventual cure for many age-related diseases A research group led by the Buck Institute for Research on Aging in collaboration with the Georgia Institute of Technology, conducted the study that pinpoints what is going wrong with the biological clock underlying the limited division of human adult stem cells as they age.

We demonstrated that we were able to reverse the process of aging for human adult stem cells by intervening with the activity of non-protein coding RNAs originated from genomic regions once dismissed as non-functional genomic junk, said Victoria Lunyak, Ph.D., associate professor at the Buck Institute for Research on Aging.

Adult stem cells are important because they help keep human tissues healthy by replacing cells that have gotten old or damaged. Theyre also multipotent, which means that an adult stem cell can grow and replace any number of body cells in the tissue or organ they belong to. However, just as the cells in the liver, or any other organ, can get damaged over time, adult stem cells undergo age-related damage. And when this happens, the body cant replace damaged tissue as well as it once could, leading to a host of diseases and conditions. But if scientists can find a way to keep these adult stem cells young, they could possibly use these cells to repair damaged heart tissue after a heart attack; heal wounds; correct metabolic syndromes; produce insulin for patients with type 1 diabetes; cure arthritis and osteoporosis and regenerate bone.

The team began by hypothesizing that DNA damage in the genome of adult stem cells would look very different from age-related damage occurring in regular body cells. They thought so because body cells are known to experience a shortening of the caps found at the ends of chromosomes, known as telomeres. But adult stem cells are known to maintain their telomeres. Much of the damage in aging is widely thought to be a result of losing telomeres. So there must be different mechanisms at play that are key to explaining how aging occurs in these adult stem cells, they thought.

Researchers used adult stem cells from humans and combined experimental techniques with computational approaches to study the changes in the genome associated with aging. They compared freshly isolated human adult stem cells from young individuals, which can self-renew, to cells from the same individuals that were subjected to prolonged passaging in culture. This accelerated model of adult stem cell aging exhausts the regenerative capacity of the adult stem cells. Researchers looked at the changes in genomic sites that accumulate DNA damage in both groups.

We found the majority of DNA damage and associated chromatin changes that occurred with adult stem cell aging were due to parts of the genome known as retrotransposons, said King Jordan, Ph.D., associate professor in the School of Biology at Georgia Tech.

Retroransposons were previously thought to be non-functional and were even labeled as junk DNA, but accumulating evidence indicates these elements play an important role in genome regulation, he added.

While the young adult stem cells were able to suppress transcriptional activity of these genomic elements and deal with the damage to the DNA, older adult stem cells were not able to scavenge this transcription. New discovery suggests that this event is deleterious for the regenerative ability of stem cells and triggers a process known as cellular senescence.

By suppressing the accumulation of toxic transcripts from retrotransposons, we were able to reverse the process of human adult stem cell aging in culture, said Lunyak.

Furthermore, by rewinding the cellular clock in this way, we were not only able to rejuvenate aged human stem cells, but to our surprise we were able to reset them to an earlier developmental stage, by up-regulating the pluripotency factors the proteins that are critically involved in the self-renewal of undifferentiated embryonic stem cells. she said.

Next the team plans to use further analysis to validate the extent to which the rejuvenated stem cells may be suitable for clinical tissue regenerative applications.

The study was conducted by a team with members from the Buck Institute for Research on Aging, the Georgia Institute of Technology, the University of California, San Diego, Howard Hughes Medical Institute, Memorial Sloan-Kettering Cancer Center, International Computer Science Institute, Applied Biosystems and Tel-Aviv University.

Citation: Inhibition of activated pericentromeric SINE/Alu repeat transcription in senescent human adult stem cells reinstates self-renewal. Cell Cycle, Volume 10, Issue 17, September 1, 2011

About the Buck Institute for Research on Aging The Buck Institute is the first freestanding institute in the United States that is devoted solely to basic research on aging and age-associated disease. The Institute is an independent nonprofit organization dedicated to extending the healthspan, the healthy years of each individuals life. Buck Institute scientists work in an innovative, interdisciplinary setting to understand the mechanisms of aging and to discover new ways of detecting, preventing and treating conditions such as Alzheimers and Parkinsons disease, cancer, cardiovascular disease and stroke. Collaborative research at the Institute is supported by new developments in genomics, proteomics and bioinformatics technology. For more information: http://www.thebuck.org.

About the Georgia Institute of Technology The Georgia Institute of Technology is one of the world's premier research universities. Ranked seventh amongU.S. News & World Report's top public universities, Georgia Tech has more than 20,000 students enrolled in its Colleges of Architecture, Computing, Engineering, Liberal Arts, Management and Sciences and is among the nation's top producers of women and minority engineers.The Institute offers research opportunities to both undergraduate and graduate students and is home to more than 100 interdisciplinary units plus the Georgia Tech Research Institute. For more information: http://www.gatech.edu.

Read more from the original source:
Scientists Turn Back the Clock on Adult Stem Cells Aging ...